BioSpace News Archive

Pfizer Inc. announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company’s common stock, payable September 3, 2024, to holders of the Common Stock of record at the close of business on July 26, 2024.

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company, announced that it intends to offer and sell shares of its common stock.

Harbour BioMed (the “Company"; HKEX: 02142) announces that it has resubmitted the Biologics License Application (BLA) of batoclimab (HBM9161) to the National Medical Products Administration (NMPA) of China for the treatment of generalized myasthenia gravis (gMG).

Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.

Hi-Tech Pharmaceuticals moves into its Phase two launch of PRO IGF-1®.

Medtronic plc today announced that Karen Parkhill will resign as executive vice president and chief financial officer to accept the role of chief financial officer for HP Inc.

The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, proudly introduces the market’s first innovative lyophilized Next-Generation Sequencing library preparation kit.

MicroVention, Inc. announced that the LVIS™ EVO™ Intraluminal Support Device is now commercially available in the United States for the treatment of wide neck intracranial aneurysms.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) today announced dosing of the first patient in the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.

MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm is pleased to announce its role in aiding CamDiab’s artificial pancreas software, CamAPS FX, in achieving U.S. Food and Drug Administration (FDA) clearance.